How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Phosphatidylinositol-3-Kinase Gamma (PI-3-Ky)

Organization name

Max-Planck-Innovation GmbH

Profile

Background

Phosphatidylinositol 3-kinase p110gamma (PI3Kgamma), the only member of the PI3K-family of kinases known to be linked to G protein-coupled receptors, has gained increasing attention as a promising drug target for the treatment of inflammatory disease.
Extensive target-validation data are available, which are derived from studies using both pharmacological and genetic tools. More recent findings have uncovered further therapeutic applications for PI3Kgamma inhibitors, opening up potentially huge opportunities for these drugs (1).

Licensing Offer

Max Planck Society through its licensing agency Max Planck Innovation GmbH invites interested licensees pursuing work related to and utilizing Phosphatidylinositol 3 -kinase p110 gamma (PI3Kgamma) to consider to join the already existing pool of licensees by obtaining a non-exclusive license for the broad intellectual property rights on Phosphatidylinositol 3-kinase p110gamma (PI3Kgamma), e.g. in the fields of drug development and/or diagnostics and/or production and/or research.

Patent Information

US issued patent US 5,885,777 Mar 23, 1999
EP issued patent EP 0786004 Aug 08, 2001 valid in AT,CH,DE,DK,FR,GB
JP issued patent JP 3949162 July 25, 2007
CA patent pending

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries